Compare Regeneron Pharmaceuticals Inc (REGN) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Wipro Limited — how do they compare? Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B), while Wipro Limited trades at $1.69 (market cap $16.36B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 4.7× Wipro Limited's market cap, and Wipro Limited pays the higher dividend (5.19%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Wipro Limited for 41 Days on average.
| REGN | WIT | |
|---|---|---|
Market Cap | $76.40B | $16.36B |
Volume | 626,381 | 6,583,554 |
Sector | Health | Technology |
52-Week High | $852.03 | $3.06 |
52-Week Low | $557.73 | $1.61 |
Typical Hold Time | 107 Days | 41 Days |
Enterprise Value | $71.12B | $14.47B |
Dividend Yield | 0.51% | 5.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Wipro (WIT) trades at $1.67, down 0.6% with bearish technical signals despite recent gap-up momentum. The company maintains solid fundamentals with $890.88B revenue and 13.92% net margin in 2025, though recent quarters show earnings misses. Analyst sentiment is mixed with only 19% buy ratings, while AI partnerships and productivity gains provide growth catalysts.
Wipro presents a cautious opportunity with reasonable valuation (P/E 12.78) but faces execution risks amid competitive IT services market. The stock's outlook depends on reversing recent earnings misses while leveraging AI initiatives that have already boosted productivity equivalent to 20,000 workers according to company reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
